Covalasent Plasma may be a promising and safe treatment option for COVID-19

"Covalasent Plasma may be a promising and safe treatment option for COVID-19"

जनकल्याण रक्तपेढी,पुणेचा सहभाग असलेल्या ICMR च्या वरील संशोधनाच्या उपक्रमात निघालेले निष्कर्ष आपल्याला Indian J Med Res मधे वाचायला मिळतील.Postgraduate Institute of Medical Education & Research, Chandigarh या मान्यवर संस्थेने लिहिलेल्या review article मधे खालील माहिती वाचायला मिळते :-

"Convalescent plasma(CP) therapy is one of the promising therapies being tried for COVID-19 patients.This passive immunity mode involves separating preformed antibodies against SARS-CoV-2 from a

recently recovered COVID-19 patient and infusing it into a patient with active disease or an exposed individual for prophylaxis. Its advantages include ease of production, rapid deployment, specificity against the target infectious agent, and scalability. In the current pandemic, it has been used on a large scale across the globe and also in India. However, unequivocal proof of efficacy and effectiveness in COVID-19 is still not available.Various CP therapy parameters such as donor selection, antibody

quantification, timing of use, and dosing need to be considered before its use. The current review attempts to summarize the available evidence and provide recommendations for setting up CP protocols in clinical and research settings.

"Covalasent Plasma may be a promising and safe treatment option for COVID-19" and is feasible in the Indian setting.Its efficacy in this setting remains to be unequivocally

established.Further research on donor selection,antibody cut-offs, precise indications of use and dosing is required before more widespread CP use becomes possible. Emerging evidence points out

the necessity of measuring antibody titres in infused plasma units and selecting high titre units for infusion.

The development of more potent modalities such as hyper-immune globulins would be the next step in enhancing passive

immune transfer-based therapeutics for COVID-19.